SCHEMBL3405897

SCHEMBL3405897

Cc1cc(S(=O)(=O)N2CCCCC2CCC(=O)N2CCC(CNC(=O)c3ccccc3)(N3CCN(C)CC3)CC2)c(C)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HCN4 Q9Y3Q4 1/20 0.41
HCN1 O60741 4/20 0.40
SLC6A9 P48067 1/20 0.40
TP53 P04637 3/20 0.38
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
LMNA P02545 1/20 0.37
THRB P10828 1/20 0.37
OPRM1 P35372 2/20 0.36
SIGMAR1 Q99720 2/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3402481 0.93 TP53 (0.37) HCN4HCN1SLC6A9TP53HCRTR1
SCHEMBL3409349 0.92 HCN4 (0.37) HCN4HCN1SLC6A9TP53HCRTR1
SCHEMBL3407032 0.91 HCN4 (0.40) HCN4HCN1SLC6A9TP53HCRTR1
SCHEMBL3405986 0.91 MC4R (0.40) HCN4TP53LMNA
SCHEMBL3409770 0.90 HCRTR1 (0.40) HCN4HCN1TP53HCRTR1HCRTR2
SCHEMBL3408874 0.88 HCRTR1 (0.38) HCRTR1HCRTR2LMNATDP1
SCHEMBL3407853 0.87 HCRTR1 (0.37) HCRTR1HCRTR2LMNATDP1
SCHEMBL4374697 0.85 HCRTR1 (0.40) HCRTR1HCRTR2THRB
SCHEMBL3407195 0.85 HCRTR1 (0.39) HCRTR1HCRTR2
SCHEMBL3406273 0.81 HCRTR1 (0.36) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541573-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-09-24 US claimed
EP-2254867-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal Gmbh (DE) 2010-12-01 EP claimed
US-20090298812-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-12-03 US claimed
WO-2009109364-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-11 WO claimed
US-8541573-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-09-24 US disclosed
EP-2254867-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal Gmbh (DE) 2010-12-01 EP disclosed
US-20090298812-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-12-03 US disclosed
WO-2009109364-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298812-A1 Substituted Sulfonamide Compounds BDKRB1, BDKRB2, TRPV1 HCN4 483/4885HCN1 426/4885SLC6A9 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.